Zenyaku Kogyo
5-6-15 Otsuka, Bunkyo-ku, Tokyo, 112-8650, Japan
Overview
Zenyaku Kogyo is a privately-held Japanese pharmaceutical company with headquarters in Tokyo. The company is marketing in Japan dermatological and anti-cancer drugs including RituxanTM, an anti-CD20 antibody for the treatment of B-cell Non-Hodgkin’s Lymphoma. The company also has an OTC consumer health care business. Zenyaku Kogyo’s ongoing research interests are focused on cancer, autoimmune diseases, and antibody therapeutics.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Life Science
- Pharmaceutical
Investment portfolio
- Theraclone Sciences
Participated · Series B · Mar 2013
Theraclone Sciences uses its I-STAR™ technology platform to rapidly screen and identify rare, therapeutically relevant human monoclonal antibodies from immunologically relevant donors. The company has discovery collaborations with Pfizer, Zenyaku Kogyo and the International AIDS Vaccine Research Initiative. Theraclone has two proprietary antibody programs in clinical development targeting pandemic/seasonal influenza and human cytomegalovirus (HCMV). Proceeds from the recent financing will advance those clinical programs and support ongoing discovery projects using the I-STAR platform. Management cites progress in lead development programs and the Pfizer collaboration as indicators of R&D strength. The company is headquartered in Seattle. Theraclone Sciences develops novel therapeutic human monoclonal antibodies for infectious disease and cancer using its I-STAR™ discovery platform. The platform is designed to rapidly screen and identify rare, potent and therapeutically relevant human antibodies from immunologically relevant donors. Theraclone isolates candidates that can be scaled for industrial production and that the company says may offer safety and broad patient relevance. The company is privately held and has existing venture backers including ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Amgen Ventures and Alexandria Real Estate Equities. Recent milestones cited by management include a discovery collaboration with Pfizer and the anticipated near-term initiation of Theraclone’s first clinical trial. Proceeds from the latest financing will support ongoing discovery projects and advance clinical programs.
Team
No current team members are available.